Navigation Links
Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
Date:7/23/2013

New York, NY (PRWEB) July 23, 2013

Signal Genetics today announced that the results of a retrospective Weill Cornell validation study of BreastPRS, a novel series of prognostic and molecular profiling algorithms for breast cancer, has been published in the medical journal ‘Breast Cancer Research and Treatment’. Signal Genetics, LLC, is a privately held molecular diagnostic company based in New York, NY and Little Rock, AR.

Ryan Van Laar, Ph.D., Head of Bioinformatics & New Product Development at Signal Genetics said “We are excited about the results of this independent study, which determines that our BreastPRS test has the potential to provide physicians improved breast cancer prognostication and more critical personalized information. It is now much more than a viable alternative.”

The publication is titled “BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.”[1]. The study was performed by re-analyzing breast cancer tissue from 246 Weill Cornell patients whose tissue had previously been analyzed with Oncotype DX® by Genomic Health® (CA) . Gene expression analysis and BreastPRS calculations were performed in Signal Genetics’ CLIA-certified laboratory in Little Rock, AR.

The correlation between recurrence score and risk groups generated from the Oncotype DX and BreastPRS methods was highly statistically significant (P < 0.0001). Notably BreastPRS was found to reclassify Oncotype DX intermediate-risk patients into two groups with significant differences in recurrence free survival, potentially offering physicians an alternative method of breast cancer prognostication, which includes molecular grade and molecular subtyping algorithms to provide a comprehensive personalized analysis of each patient’s disease.

BreastPRS has also been used by researchers at the Windber Research Institute (Windber, PA) to examine the impact of recent ASCO/CAP guideline changes for determining ER status. The study was published in the Annals of Surgical Oncology (2013 Jan; 20(1): 87-93)

Signal Genetics is seeking licensing partners to further develop BreastPRS as a stand-alone prognostic test for patients with breast cancer. For more information contact Signal Genetics by emailing info(at)signalgenetics(dot)com.

[1] Timothy M. D’Alfonso, et al. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence. Breast Cancer Research and Treatment. June 2013, Volume 139, Issue 3, pp 705-715

Genomic Health and Oncotype DX are registered trademarks of Genomic Health, Inc.

Read the full story at http://www.prweb.com/releases/signalgenetics/breastprs/prweb10947060.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Needle beam could eliminate signal loss in on-chip optics
2. Physicists skirt thermal vibration, transfer optical signal via mechanical oscillator
3. Laser-like photons signal major step towards quantum Internet
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. Signal-Health Develops Easy Checklist to Identify Possible Sweating Issues in Horses
6. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
7. Interleukin Genetics Reports Third Quarter 2011 Financial Results
8. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
9. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
10. Cytogenetics - Technologies, Markets and Companies
11. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2019)... ... 2019 , ... At the most recent stem cell training course ... under the R3 Heroes Program. The Veterans included individuals and families from all over ... to nominate a military Veteran, teacher or first responder to receive a regenerative therapy ...
(Date:7/9/2019)... , ... July 08, 2019 , ... ... The company’s SmartLight Indicator was recognized as the 2019 Innovative Product of the ... forward. The prestigious awards were during Sensors Expo & Conference 2019, ...
(Date:6/26/2019)... LAS VEGAS (PRWEB) , ... June 26, 2019 , ... ... biofield energy treatment on improving physicochemical properties of Magnesium Gluconate, which can prove to ... Over 125% alteration of characteristic differentiation peak, change in crystallite size , ...
(Date:6/18/2019)... ... 18, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. ... knee. This IND is the first of several planned clinical trials which will ...
Breaking Biology Technology:
(Date:7/17/2019)... ... July 17, 2019 , ... Georgia ... pediatric urologists are among the professionals honored in U.S. News & World ... the country’s pediatric healthcare landscape. , Georgia Urology’s wholly-owned subsidiary, Georgia ...
(Date:7/10/2019)... ... 10, 2019 , ... Inference Solutions , a global ... announced its role in Pizza Hut Australia’s digital transformation initiative to ... key part of this initiative is implementation of an automated call-steering application that ...
(Date:6/27/2019)... (PRWEB) , ... June 27, 2019 , ... Lighting designers ... Illuminating Energy Society (IES), which honored the designers for creating both engaging and energy ... 701B Street , an office tower in San Diego, California earned an IES ...
Breaking Biology News(10 mins):